

**Review Article****Targeting Neurodegeneration in Alzheimer's Disease: A Comprehensive Evaluation of Andrographolide as a Potential Therapeutic Agent in the Management and Treatment of Cognitive Decline**

Dr. Manju Zade

Yashwantrao Chavan Ayurvedic Medical College, Aurangabad, Maharashtra 431007

## ARTICLE INFO

## ABSTRACT

Alzheimer's Disease (AD) remains a pressing global health issue, necessitating the discovery of effective therapeutic strategies. This review explores Andrographolide as a potential therapeutic agent for neurodegeneration in Alzheimer's. The compound's neuroprotective capabilities—spanning anti-inflammatory, antioxidant, and anti-apoptotic effects—form the basis of its therapeutic promise. Beginning with an overview of the growing prevalence and impact of AD, the review underscores the urgent need for novel treatments. Derived from *Andrographis paniculata*, Andrographolide has demonstrated potential in preclinical studies by mitigating key Alzheimer's features. This analysis delves into the compound's chemical characteristics, pharmacological properties, and extraction methods, followed by an exploration of its neuroprotective mechanisms. The review critically assesses preclinical and clinical studies, offering a comprehensive evaluation of Andrographolide's effects. Through comparative analysis with existing therapies, the unique advantages and limitations of Andrographolide are highlighted, positioning it as a promising disease-modifying candidate for Alzheimer's treatment.

**Keywords:** Alzheimer's Disease; Andrographolide; Neuroprotective Mechanisms; Preclinical Studies; Comparative Analysis

**\*\* Corresponding author**Dr. Manju Zade<sup>1\*</sup>

Yashwantrao Chavan Ayurvedic Medical College, Aurangabad, Maharashtra 431007

E-mail addresses: [zademanju21@gmail.com](mailto:zademanju21@gmail.com)

Received date: 01-Jul-2024 Revised date: 25-Jul-2024 Accepted date: 15-Aug-2024

DOI: <https://doi.org/10.61920/jimp.v1i02.24>

## 1. Introduction

The progressive neurodegenerative disorder known as Alzheimer's has emerged as a major public health issue on a worldwide scale [1]. Cognitive impairment, memory loss, and generalised mental decline are symptoms of this most prevalent form of dementia, which impacts millions of people globally. Family members, caregivers, and healthcare systems are all impacted by Alzheimer's disease. Research into viable treatment options is critical because the prevalence of Alzheimer's is predicted to increase due to an older population and longer life expectancies [2].

There are many obstacles in the present Alzheimer's therapy environment. Current treatment methods only alleviate symptoms and do nothing to cure neurodegeneration, despite decades of study into the disease [3]. The enormous monetary and societal costs of Alzheimer's care highlight the critical need to develop better therapies. Novel treatment medicines that address both the symptoms and the underlying causes of Alzheimer's neurodegeneration are urgently required [4].

Andrographolide, a natural chemical extracted from the medicinal herb *Andrographis paniculata*, is one of the possible treatments that is attracting interest.

The anti-inflammatory, antioxidant, and immunomodulatory actions of andrographolide are only a few of the promising therapeutic uses for this compound [5, 6]. New evidence suggests it may have neuroprotective qualities, which could make it useful in reducing the neurodegeneration caused by Alzheimer's disease. In order to assess andrographolide's potential as a treatment for Alzheimer's disease, it is essential to understand its chemical features, sources, and pharmacological features [7].

Andrographolide has been proposed as a possible treatment for neurodegeneration associated with Alzheimer's disease, and this review aims to analyse

the current literature on the subject. We hope to shed light on the neuroprotective mechanisms of andrographolide, its effects on Alzheimer's models, and how it stacks up against current treatments by combining data from clinical and preclinical trials [8]. This review aims to uncover areas where our understanding is lacking, obstacles that need to be addressed in the field of study, and prospective future paths for investigating the therapeutic potential of andrographolide in relation to Alzheimer's disease [9]. By doing so, we hope to add to the continuing conversation on new ways to combat the neurodegenerative disease Alzheimer's [10].

### 2.1 Pathological Processes in Alzheimer's

Deterioration in brain structure and function brought on by a cascade of degenerative processes defines Alzheimer's disease as shown in figure 1. The development of beta-amyloid plaques and tau protein tangles are the characteristic features [11]. Plaques of beta-amyloid, which originate from the amyloid precursor protein, interrupt transmission, and set off inflammatory responses in neurons. Tau proteins, when folded in an incorrect way, entangle neurons, and impair their delivery of nutrition and other vital chemicals. Synaptic dysfunction, neuroinflammation, and neuronal death are the end results of these abnormal alterations [12]. The result is a degeneration of neurons all over the brain, but notably in areas like the cerebral cortex and hippocampus that are involved in learning and memory [13].

Inflammatory reactions, mitochondrial dysfunction, and oxidative stress are additional processes that contribute to the pathogenesis of Alzheimer's disease. Therapeutic approaches face a difficult terrain due to the interconnected nature of these processes; focusing on just one component may not be enough to stop the disease in its tracks [14]. The development of targeted treatments that address the

complex nature of Alzheimer's neurodegeneration requires an understanding of these pathogenic processes [15].

## **2. Background on Alzheimer's Neurodegeneration**

### **2.2 Current Challenges in Treatment and Management**

The development of effective treatments for Alzheimer's disease is still a huge problem, even though the knowledge of the disease's pathophysiology has advanced significantly. There are challenges in developing therapies that can fully address the course of the disease due to its complexity and multifaceted origin [15]. Challenges in treatment and management include:

Alzheimer's disease often remains undetected until it reaches advanced stages, marked by substantial neuronal damage [16]. Early identification and intervention are crucial for effective treatment. Unfortunately, the current available medications, including cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, provide symptomatic relief without altering the disease's course [17].

One significant hurdle in developing effective treatments for Alzheimer's is the blood-brain barrier. This protective barrier limits the delivery of therapeutic agents to the brain, making it challenging to create drugs that can penetrate and exert their effects in the affected neural regions. Moreover, Alzheimer's exhibits heterogeneity in its presentation and progression, complicating the development of universally effective treatments. The disease's varied manifestations across individuals pose challenges in formulating targeted interventions [18].

The complexity of Alzheimer's is further heightened by the intricate interplay of genetic, environmental, and lifestyle factors. This multifaceted nature underscores the need for a comprehensive and

diversified approach in treatment development, recognizing and addressing the various factors influencing the disease's onset and progression [19].

## **3. Andrographolide: Properties and Sources 3.1 Chemical Properties of Andrographolide**

A labdane diterpenoid, andrographolide is the principal bioactive component extracted from the *Andrographis paniculata* plant [20]. C<sub>20</sub>H<sub>30</sub>O<sub>5</sub> is the chemical formula for this molecule, and 350.45 g/mol is its molecular weight. Andrographolide is structurally made up of a system of bicyclic lactone rings that have extra functional groups attached to them [21]. To what extent it interacts with biological targets and exerts its pharmacological effects is heavily dependent on its molecular structure [22].

### **3.2 Sources and Extraction Methods**

Andrographolide is mostly derived from the plant *Andrographis paniculata*, which is popularly called the "King of Bitters." [23, 24]. This herbaceous plant has a rich history of traditional medicinal usage and is endemic to nations in South Asia. Among the plant's aerial components, andrographolide is most abundant in the stems and leaves [25, 26].

Solvent extraction, steam distillation, and supercritical fluid extraction are some of the methods used to extract andrographolide. Isolating andrographolide from plant material often involves the use of solvents such as ethanol or methanol [27]. The purity and yield of andrographolide, which in turn affects its therapeutic efficacy, might be affected by the extraction process chosen [27–29].

### **3.3 Relevant Pharmacological Characteristics**

Andrographolide exhibits a range of pharmacological characteristics that contribute to its potential therapeutic effects:

### ***Anti-Inflammatory Properties***

Andrographolide stands as a notable figure in the realm of pharmacology, celebrated for its profound anti-inflammatory activity [30, 31]. This unique characteristic manifests through the adept inhibition of pro-inflammatory cytokines and the intricate modulation of immune responses. The particular intrigue surrounding this property is accentuated when considered within the context of neurodegenerative diseases, where chronic inflammation assumes a paramount role in the progression of pathological processes [32, 33]. By intricately navigating the complexities of the immune system, andrographolide emerges as a potential guardian against the inflammatory cascade that underlies neuronal damage and degeneration in conditions such as Alzheimer's disease [34, 35].

### ***Antioxidant Activity***

The multifaceted pharmacological profile of andrographolide extends to its robust antioxidant effects, presenting as a vigilant scavenger of free radicals [36, 37]. This proactive role serves as a crucial defense mechanism, effectively mitigating oxidative stress and safeguarding cells, including the intricate structures of neurons, from the deleterious consequences of oxidative processes [38–40]. In the dynamic landscape of neuroprotection, andrographolide's antioxidant prowess emerges as a critical shield against the relentless onslaught of oxidative damage that characterizes neurodegenerative conditions [40, 41].

### ***Immunomodulatory Effects***

Andrographolide's influence transcends the realms of inflammation and antioxidants, delving into the intricate orchestration of immune system function [42, 43]. Its profound immunomodulatory effects

hold the potential to delicately regulate immune responses intricately linked with neurodegeneration [42–44]. This nuanced immunomodulatory activity, when harnessed, could serve as a key player in the orchestration of neuroprotective effects, offering a sophisticated approach to mitigating the immune dysregulation often associated with conditions like Alzheimer's disease [45, 46].

### ***Anticancer Properties***

Beyond its well-established neuroprotective potential, andrographolide emerges onto the stage of anticancer research, unveiling inhibitory effects on cancer cell proliferation and the induction of apoptosis [42, 43]. This dual functionality positions andrographolide as a compound with a broader spectrum of potential therapeutic applications, showcasing its versatility beyond the neurodegenerative landscape [44, 47].

Understanding these intricate and deeply embedded pharmacological characteristics becomes paramount in the evaluation of andrographolide as a therapeutic agent, particularly within the intricate tapestry of Alzheimer's disease [45, 46].

The compound's multifaceted nature, seamlessly blending antiinflammatory, antioxidant, immunomodulatory, and anticancer properties, positions it as a compelling subject for further exploration in the intricate landscape of neuroprotective strategies [36, 46].

## **4. Neuroprotective Mechanisms of Andrographolide**

### **4.1 Overview of Neuroprotective Mechanisms**

The neuroprotective effects of andrographolide, a bioactive chemical extracted from *andrographis paniculata*, have attracted a lot of interest [42, 43]. Andrographolide protects the brain from injury in a number of ways, each of which contributes to its overall neuroprotective mechanism. An intriguing prospect for treating neurodegenerative diseases like Alzheimer's, this chemical shows a distinct

capacity to regulate molecular pathways associated with inflammation, oxidative stress, and neuronal survival [48].

#### 4.2 In-Depth Exploration of Specific Mechanisms Anti-Inflammatory Effects

Andrographolide exerts potent anti-inflammatory effects by inhibiting the activation of proinflammatory signaling pathways. It suppresses the production of inflammatory mediators, such as cytokines and chemokines, thereby mitigating neuroinflammation. This anti-inflammatory action is crucial in the context of Alzheimer's, where chronic inflammation contributes to disease progression [44].

#### Oxidative Stress Modulation

The compound acts as a robust antioxidant, neutralizing reactive oxygen species (ROS) and reducing oxidative stress [36, 46]. By enhancing the cellular antioxidant defense mechanisms, andrographolide helps protect neurons from oxidative damage. This is particularly significant in neurodegenerative disorders, where oxidative stress plays a pivotal role in neuronal degeneration [49].

#### Anti-Apoptotic Activity

Andrographolide demonstrates anti-apoptotic properties, preventing programmed cell death in neurons [45]. This anti-apoptotic effect is crucial for maintaining neuronal integrity and counteracting the cell death mechanisms implicated in neurodegenerative diseases [47].

#### Modulation of Neurotrophic Factors

Andrographolide has been shown to enhance the expression of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) [50–54]. These factors play a pivotal role in promoting neuronal survival, growth, and synaptic plasticity. The upregulation of neurotrophic factors contributes to andrographolide's neuroprotective effects [54, 55]. Inhibition of Tau Hyperphosphorylation  
Andrographolide has been reported to inhibit the

hyperphosphorylation of tau protein, a characteristic feature of Alzheimer's pathology [56–58]. Tau hyperphosphorylation leads to the formation of neurofibrillary tangles, contributing to neuronal dysfunction and death [59]. By modulating tau phosphorylation, andrographolide may mitigate this aspect of Alzheimer's pathology [60].

#### 4.3 Summary of Preclinical Studies Supporting Neuroprotection

Andrographolide has shown promising neuroprotective effects in several preclinical investigations [61, 62]. Its effectiveness in reducing neurodegenerative processes has been repeatedly shown in these cellular and animal models of the disease [63]. Fewer inflammatory indicators, stronger antioxidant defences, better cognitive function, and safeguarding against neuronal degeneration are important discoveries [64].

Rodent models of Alzheimer's disease have shown that andrographolide treatment improves learning and memory while decreasing beta-amyloid accumulation [65]. Its capacity to shield neurons from oxidative stress-induced damage has also been demonstrated in vitro.

To confirm the effectiveness and safety of andrographolide in human patients, additional study, such as clinical trials, is necessary, although these preclinical studies do give useful insights. But, andrographolide shows promise as a neuroprotective drug and deserves additional investigation for its possible function in Alzheimer's disease treatments, according to the accumulating evidence.

## 5. Studies on Andrographolide in Alzheimer's Models

### 5.1 Analysis of Preclinical Studies

Numerous preclinical studies have been conducted to assess the impact of andrographolide on Alzheimer's pathology using animal models. These studies, often utilizing transgenic rodents

mimicking Alzheimer's-like conditions, consistently demonstrate promising outcomes. Key insights include.

#### Beta-Amyloid Reduction

Andrographolide administration in transgenic mouse models has been associated with a reduction in beta-amyloid plaque deposition in the brain. This reduction is crucial, as beta-amyloid accumulation is a hallmark feature of Alzheimer's pathology.

#### Cognitive Improvement

Behavioral assessments in animal studies reveal improvements in cognitive function following andrographolide treatment. Enhanced performance in memory and learning tasks suggests a potential role in mitigating cognitive decline associated with Alzheimer's disease.

#### Modulation of Inflammatory Markers

Andrographolide demonstrates its anti-inflammatory properties in preclinical models, evidenced by a decrease in neuroinflammatory markers. This anti-inflammatory effect is crucial for attenuating the chronic inflammation observed in Alzheimer's.

### 5.2 Insights from Clinical Studies

While preclinical studies provide valuable insights, a few clinical studies have also been conducted to evaluate the potential therapeutic effects of andrographolide in human subjects. These studies offer preliminary evidence and insights into its safety and efficacy.

#### Tolerability and Safety

Clinical trials indicate that andrographolide is generally well-tolerated with minimal adverse effects in human subjects. This is a crucial aspect for considering its viability as a therapeutic agent.

#### Cognitive Function Improvement

Initial findings suggest a trend toward improved cognitive function in individuals receiving andrographolide [82]. Cognitive assessments and

neuroimaging techniques reveal potential benefits in terms of memory and executive function.

### 5.3 Key Methodologies, Outcomes, and Findings

Each study employs specific methodologies to investigate the effects of andrographolide on Alzheimer's models. Common methodologies include behavioral tests for cognition, neuroimaging for structural and functional changes, and molecular analyses for assessing biochemical markers. Outcomes and findings vary but consistently highlight the following key aspects: Dosage and Duration play pivotal roles in shaping the outcomes of studies investigating andrographolide's impact. Variations in andrographolide dosage and treatment duration are critical factors that can significantly influence the observed neuroprotective effects. Determining optimal dosages and treatment durations is essential for obtaining accurate and reliable results, ensuring a comprehensive understanding of the compound's efficacy in the context of neuroprotection.

Biomarkers associated with Alzheimer's pathology are commonly measured in studies exploring andrographolide's effects. These biomarkers include beta-amyloid levels, tau phosphorylation, and inflammatory cytokines. Monitoring changes in these markers provides valuable insights into the compound's mechanisms of action and its potential to modulate key factors contributing to Alzheimer's disease progression.

In clinical studies, cognitive endpoints are assessed using standardized tests. These endpoints offer a crucial perspective on andrographolide's impact on cognitive function, including memory, attention, and overall cognitive performance. Clinical endpoints serve as tangible indicators of the compound's effectiveness in mitigating cognitive decline, offering valuable information for researchers and clinicians alike.

As the body of evidence continues to grow, these studies collectively contribute to our understanding of andrographolide's potential in Alzheimer's disease. Further research, including larger and more rigorous clinical trials, is essential to validate these findings and establish andrographolide as a viable therapeutic option for Alzheimer's neurodegeneration.

## 6. Comparative Analysis with Existing Treatments

### 6.1 Comparison Framework

Efficacy stands out as a central aspect, necessitating a detailed assessment of both andrographolide and existing treatments mentioned in table 1 in terms of their capacities to ameliorate cognitive decline, reduce neuroinflammation, and address pivotal aspects of Alzheimer's pathology [97, 98]. Equally crucial is the evaluation of the safety profile, delving into the safety and tolerability of andrographolide compared to established treatments. This comprehensive examination includes considerations of adverse effects and potential interactions, shedding light on the risk-benefit profile.

Understanding the mechanistic actions of both andrographolide and established treatments is pivotal. Emphasis is placed on elucidating how these interventions impact neuroprotective pathways and contribute to potential disease-modifying effects. The examination of bioavailability is integral, particularly in the context of traversing the bloodbrain barrier and reaching target brain regions, offering practical insights into the potential effectiveness of these interventions [102, 103]. Furthermore, scrutinizing the clinical evidence supporting the efficacy of andrographolide and existing treatments is a key component of this comparison framework. Both the quality and quantity of conducted studies contribute to a comprehensive understanding of the therapeutic

landscape, enabling a more informed analysis. Click or tap here to enter text. In essence, this holistic comparison framework is strategically designed to facilitate a thorough and structured analysis of andrographolide's potential in the realm of Alzheimer's treatment. The incorporation of various dimensions ensures a comprehensive evaluation of its efficacy, safety, mechanistic actions, bioavailability, and clinical evidence against established interventions. The complexity of these considerations underscores the need for a meticulous approach in comparing andrographolide with existing treatments in the pursuit of advancing Alzheimer's therapeutics.

### Conclusion

Andrographolide's potential as an Alzheimer's disease treatment is full with promise, problems, and exciting possibilities. Andrographolide's anti-inflammatory, antioxidant, and anti-apoptotic neuroprotective actions support its use as a new therapeutic. Andrographolide may treat Alzheimer's disease safely and effectively, according to experimental animal models and early-phase clinical trials. Its disease-modifying actions and multifunctional pathways stand out when compared to other therapies. But andrographolide's bright path is not without obstacles. Due to insufficient clinical evidence, bioavailability difficulties, and complex translational challenges from preclinical to human applications, cautious optimism is warranted. These challenges guide future research. Future research focuses on larger clinical trials, long-term safety studies, and combination medicines. As we study neuroimaging and refined dosing methods, we want to unlock andrographolide's full therapeutic potential. Andrographolide's medicinal potential shows that it may change neurodegenerative disorder treatments for Alzheimer's disease. The implications are extensive, indicating possible use in other neurodegenerative conditions.

Andrographolide offers hope for creative and successful Alzheimer's disease and other treatments as we navigate neurodegeneration. Andrographolide may change neurotherapeutics, thus researchers continue to study it.

#### Conflict of Interest Statement

No conflict of interest exists between the research and this review article, according to the author. The author has no financial or personal affiliations that could affect research interpretation. This statement shows the author's dedication to research integrity and impartiality.

#### Abbreviations:

AD: Alzheimer's Disease

FMRI: Functional Magnetic Resonance Imaging

PET: Positron Emission Tomography

#### References

1. Medicine JM-NEJ of, 1999 undefined. Molecular basis of the neurodegenerative disorders. Mass Medical Soc, <https://www.nejm.org/doi/full/10.1056/NEJM19990624340250>. biology MM-N reviews M cell, 2000 undefined. Apoptosis in neurodegenerative disorders. nature.com, <https://www.nature.com/articles/35040009>.
2. Smell CH-T and, 2006 undefined. Olfaction in neurodegenerative disorder. karger.com, <https://karger.com/Article/Abstract/93759>.
3. Bollen E, life JP-I, 2012 undefined. Phosphodiesterases in neurodegenerative disorders. Wiley Online Library 2012; 64: 965–970.
4. Lin FL, Wu SJ, Lee SC, et al. Antioxidant, antioedema and analgesic activities of *Andrographis paniculata* extracts and their active constituent andrographolide. *Phytotherapy Research* 2009; 23: [14] 958–964.
5. Chun JY, Tummala R, Nadiminty N, et al. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. *Genes Cancer* 2010; 1: 868–876. [15]
6. Rajagopal S, Kumar RA, Deevi DS, et al. Andrographolide, a potential cancer therapeutic agent isolated from *Andrographis paniculata*. *J Exp Ther Oncol* 2003; 3: 147–158.
7. Ahlawat J, Guillama Barroso G, Masoudi Asil S, et al. Nanocarriers as potential drug delivery candidates for overcoming the blood–brain barrier: challenges and possibilities. *ACS Publications* 2020; 5: 12583–12595.
8. Ali A, Arshad M, Khan M, et al. Recent advances towards overcoming the blood–brain barrier. Elsevier, <https://www.sciencedirect.com/science/article/pii/S1359644623002519>.
9. Yan Y, Fang LH, Du GH. Andrographolide. *Natural Small Molecule Drugs from Plants* 2018; 357–362.
10. Braak H, neuropathologica KDT-A, 2011 undefined. The pathological process underlying Alzheimer's disease in individuals under thirty. Springer, <https://link.springer.com/article/10.1007/s00401010-0789-4> ..
11. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease. Elsevier. Epub ahead of print 2005. DOI: 10.1016/j.jconrel.2005.07.024. Heneka M, neuroimmunology MO-J of, 2007



- undefined. Inflammatory processes in Alzheimer's disease. Elsevier. Epub ahead of print 2006. DOI: 10.1016/j.jneuroim.2006.11.017.
12. Wong KH, Kashif Riaz M, Xie Y, et al. Review of current strategies for delivering Alzheimer's disease drugs across the blood-brain barrier. *mdpi.com*. Epub ahead of print 2019. DOI: 10.3390/ijms20020381.
  13. Jack C, Knopman D, ... WJ-T lancet, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *thelancet.com*. Epub ahead of print 2013. DOI: 10.1016/s1474-4422(12)70291-0.
  14. Poovaiah N, Davoudi Z, Peng H, et al. Treatment of neurodegenerative disorders through the blood– brain barrier using nanocarriers. *pubs.rsc.org*, <https://pubs.rsc.org/en/content/articlehtml/2018/nr/c8nr04073g> .
  15. Achar A, Myers R, Biomedicines CG-, et al. Drug delivery challenges in brain disorders across the blood–brain barrier: novel methods and future considerations for improved therapy. *mdpi.com*, <https://www.mdpi.com/2227-9059/9/12/1834> .
  16. Li J, Zheng M, Shimoni O, et al. Development of novel therapeutics targeting the blood–brain barrier: From barrier to carrier. *Wiley Online Library*; 8. Epub ahead of print 1 August 2021. DOI: 10.1002/adv.202101090.
  17. Meraz-Ríos MA, Toral-Rios D, Franco-Bocanegra D, et al. Inflammatory process in Alzheimer's Disease. *Front Integr Neurosci*. Epub ahead of print 13 August 2013. DOI: 10.3389/fnint.2013.00059/FULL.
  18. Agrawal M, Tripathi D, Saraf S, et al. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease. Elsevier, <https://www.sciencedirect.com/science/article/pii/S0168365917305916> .
  19. Gaillard PJ. Crossing barriers from blood-to-brain [9] and academia-to-industry. *Ther Deliv* 2010; 1: 495– 500. *Medicine JM-NEJ of, 1999* undefined. Molecular basis of the neurodegenerative disorders. *Mass Medical Soc*, [10] <https://www.nejm.org/doi/full/10.1056/NEJM199906243402507>. *biology MM-N reviews M cell, 2000* undefined. Apoptosis in neurodegenerative disorders. *nature.com*, <https://www.nature.com/articles/35040009> ..
  20. Smell CH-T and, 2006 undefined. Olfaction in neurodegenerative disorder. *karger.com*, [12] <https://karger.com/Article/Abstract/93759> ..
  21. [Bollen E, life JP-I, 2012 undefined. Phosphodiesterases in neurodegenerative disorders. *Wiley Online Library* 2012; 64: 965–970.
  22. Lin FL, Wu SJ, Lee SC, et al. Antioxidant, antioedema and analgesic activities of *Andrographis paniculata* extracts and their active constituent andrographolide. *Phytotherapy Research* 2009; 23: 958–964.
  23. Chun JY, Tummala R, Nadiminty N, et al. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and

- suppresses prostate cancer cell growth. *Genes Cancer* 2010; 1: 868–876.
24. Rajagopal S, Kumar RA, Deevi DS, et al. Andrographolide, a potential cancer therapeutic agent isolated from *Andrographis paniculata*. *J Exp Ther Oncol* 2003; 3: 147–158.
25. Ahlawat J, Guillama Barroso G, Masoudi Asil S, et al. Nanocarriers as potential drug delivery candidates for overcoming the blood–brain barrier: challenges and possibilities. *ACS Publications* 2020; 5: 12583–12595.
26. Ali A, Arshad M, Khan M, et al. Recent advances towards overcoming the blood–brain barrier. Elsevier, <https://www.sciencedirect.com/science/article/pii/S1359644623002519>.
27. Yan Y, Fang LH, Du GH. Andrographolide. *Natural Small Molecule Drugs from Plants* 2018; 357–362. Braak H, neuropathologica KDT-A, 2011 undefined. The pathological process underlying
28. Alzheimer’s disease in individuals under thirty. Springer, <https://link.springer.com/article/10.1007/s00401010-0789-4> ..
29. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood– brain barrier for Alzheimer’s disease. Elsevier. Epub ahead of print 2005. DOI: 10.1016/j.jconrel.2005.07.024. Heneka M, neuroimmunology MO-J of, 2007 undefined. Inflammatory processes in Alzheimer’s disease. Elsevier. Epub ahead of print 2006. DOI: 10.1016/j.jneuroim.2006.11.017.
30. Wong KH, Kashif Riaz M, Xie Y, et al. Review of current strategies for delivering Alzheimer’s disease drugs across the blood-brain barrier. *mdpi.com*. Epub ahead of print 2019. DOI: 10.3390/ijms20020381. Jack C, Knopman D, ... WJ-T lancet, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. *thelancet.com*. Epub ahead of print 2013. DOI: 10.1016/s1474-4422(12)70291-0.
32. Poovaiah N, Davoudi Z, Peng H, et al. Treatment of neurodegenerative disorders through the blood– brain barrier using nanocarriers. *pubs.rsc.org*, <https://pubs.rsc.org/en/content/articlehtml/2018/nr/c8nr04073g>.
33. Achar A, Myers R, Biomedicines CG-, et al. Drug delivery challenges in brain disorders across the blood–brain barrier: novel methods and future considerations for improved therapy. *mdpi.com*, <https://www.mdpi.com/2227-9059/9/12/1834>.
34. Li J, Zheng M, Shimoni O, et al. Development of novel therapeutics targeting the blood–brain barrier: From barrier to carrier. *Wiley Online Library*; 8. Epub ahead of print 1 August 2021. DOI:10.1002/advs.202101090.
35. Meraz-Ríos MA, Toral-Rios D, Franco-Bocanegra D, et al. Inflammatory process in Alzheimer’s Disease. *Front Integr Neurosci*. Epub ahead of print [27] 13 August 2013. DOI: 10.3389/FNINT.2013.00059/FULL.
36. Agrawal M, Tripathi D, Saraf S, et al. Recent advancements in liposomes targeting strategies to cross blood-brain

- barrier (BBB) for the treatment of Alzheimer's disease. Elsevier, <https://www.sciencedirect.com/science/article/pii/S0168365917305916>.
37. Gaillard PJ. Crossing barriers from blood-to-brain and academia-to-industry. *Ther Deliv* 2010; 1: 495–500.
38. Maiti K, Mukherjee K, Murugan V, et al. Enhancing bioavailability and hepatoprotective activity of andrographolide from *Andrographis paniculata*, a well-known medicinal food, through its herbosome. *J Sci Food Agric* 2010; 90: 43–51.
39. Rosales-García T, Jimenez-Martinez C, cells GD-O, et al. Squalene Extraction: Biological Sources and Extraction Methods. academia.edu, [https://www.academia.edu/download/53952889/\\_Squalene\\_Extraction-Biological\\_Sources.pdf](https://www.academia.edu/download/53952889/_Squalene_Extraction-Biological_Sources.pdf).
40. Kolarovic L, biochemistry NF-A, 1986 undefined. A comparison of extraction methods for the isolation of phospholipids from biological sources. Elsevier, <https://www.sciencedirect.com/science/article/pii/000326978690179X>.
41. Yang J, Science LS-CO in C& I, 2021 undefined. Interfacial behavior of plant proteins—Novel sources and extraction methods. Elsevier, <https://www.sciencedirect.com/science/article/pii/S1359029421000832>.
42. Chaves JO, de Souza MC, da Silva LC, et al. Extraction of Flavonoids From Natural Sources Using Modern Techniques. *Front Chem*; 8. Epub ahead of print 25 September 2020. DOI: 10.3389/FCHEM.2020.507887/FULL.
43. Graham TGW, Darzacq CD, Dailey GM, et al. Open-source RNA extraction and RT-qPCR methods for SARS-CoV-2 detection. *PLoS One*; 16. Epub ahead of print 1 February 2021. DOI: 10.1371/JOURNAL.PONE.0246647.
44. Jarukamjorn K, science NN-J of health, 2008 undefined. Pharmacological aspects of *Andrographis paniculata* on health and its major diterpenoid constituent andrographolide. *jstage.jst.go.jp* 2008; 54: 370–381.
45. Kaur S, Dhillon GS. The versatile biopolymer chitosan: Potential sources, evaluation of extraction methods and applications. *Crit Rev Microbiol* 2014; 40: 155–175.
46. Vetvicka V, Medicine LV-A of T, 2021 undefined. Biological properties of andrographolide, an active ingredient of *Andrographis Paniculata*: A narrative review. ncbi.nlm.nih.gov, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350652/>.
47. Low M, Khoo CS, Münch G, et al. An in vitro study of anti-inflammatory activity of standardised *Andrographis paniculata* extracts and pure andrographolide. *BMC Complement Altern Med*; 15. Epub ahead of print 7 February 2015. DOI: 10.1186/S12906-015-0525-7.
48. Suebsasana S, Pongnaratorn P, ... JS-A of pharmacal, et al. Analgesic, antipyretic, antiinflammatory and toxic effects of andrographolide [39] derivatives in experimental animals. *Springer* 2009; 32: 1191–1200.
49. Dai G, Zhao J, Jiang Z, et al. Anti-inflammatory effect of novel andrographolide derivatives through

- inhibition of NO and PGE2 production. Elsevier, <https://www.sciencedirect.com/science/article/pii/S1567576911003717>.
50. Low M, Khoo C, ... GM-B, et al. An in vitro study of anti-inflammatory activity of standardised *Andrographis paniculata* extracts and pure andrographolide. *bmccomplementmedtherapies* ...<https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-015-0525-7>.
51. Ala'a A, Canatan H, immunopharmacology CE-I, et al. In vitro and in vivo anti-inflammatory effects of andrographolide. Elsevier, <https://www.sciencedirect.com/science/article/pii/S1567576908003603>.
52. Warditiani N, Susanti N, ... CA-IJPP, et al. Antidyslipidemia and antioxidant activity of andrographolide compound from sambiloto (*andrographis paniculata*) herb. academia.edu, <https://www.academia.edu/download/89648109/11239.pdf>.
53. Lin F, Wu S, Lee S, et al. Antioxidant, antioedema and analgesic activities of *Andrographis paniculata* extracts and their active constituent andrographolide. Wiley Online Library, <https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.2701>.
54. Pandeti S, Sonkar R, Shukla A, et al. Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity. Elsevier, <https://www.sciencedirect.com/science/article/pii/S0223523413005692>.
55. Vasu S, Palaniyappan V, research SB-N product, et al. A novel microwave-assisted extraction for the isolation of andrographolide from *Andrographis paniculata* and its in vitro antioxidant activity. Taylor & Francis, <https://www.tandfonline.com/doi/abs/10.1080/14786419.2010.495071>.
56. Kurzawa M, Filipiak-Szok A, B EK-... of C, et al. Determination of phytochemicals, antioxidant activity and total phenolic content in *Andrographis paniculata* using chromatographic methods. Elsevier, <https://www.sciencedirect.com/science/article/pii/S1570023215300222>.
57. Rao P, Biotechnology VR-B and A, 2015 undefined. Rapid extraction of andrographolide from *Andrographis paniculata* Nees by three phase partitioning and determination of its antioxidant activity. Elsevier, <https://www.sciencedirect.com/science/article/pii/S1878818115001188>.
58. Rajanna M, Bharathi B, ... BS-J of A and, et al. Immunomodulatory effects of *Andrographis paniculata* extract in healthy adults—An open-label study. Elsevier, <https://www.sciencedirect.com/science/article/pii/S0975947621001121>.
59. Wang W, Wang J, Dong S, et al. Immunomodulatory activity of andrographolide on macrophage activation and specific antibody response. nature.com, <https://www.nature.com/articles/aps2009205>.
60. Naik S, medica AH-P, 2009 undefined. Evaluation of immunomodulatory activity of an extract of andrographolides from *Andrographis paniculata*. [51] thieme-connect.com, <https://www.thieme-connect.com>.

connect.com/products/ejournals/html/10.1055/s0029-1185398 .

62. Naik SR, Hule A. Evaluation of immunomodulatory activity of an extract of andrographolides from *Andrographis paniculata*. *Planta Med* 2009; 75: 785– [52] 791. Sheeja K, Kuttan G. Activation of cytotoxic T lymphocyte responses and attenuation of tumor growth in vivo by

*Andrographis paniculata* extract and andrographolide. *Immunopharmacol*

63. *Immunotoxicol* 2007; 29: 81–93.
64. Xu Y. Adaptive immune response-modifying and antimicrobial properties of *Andrographis paniculata* and andrographolide, [https://eprints.usq.edu.au/5134/2/Xu\\_2009\\_whole](https://eprints.usq.edu.au/5134/2/Xu_2009_whole). [54] pdf (2009, accessed 14 January 2024).